Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med. 2003;138(10):777–86.

Article  PubMed  Google Scholar 

Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, et al. : 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.

Article  PubMed  Google Scholar 

Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382(13):1208–18.

Article  CAS  PubMed  Google Scholar 

Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, Lipiecki J, Richardt G, Iniguez A, Brunel P, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.

Article  CAS  PubMed  Google Scholar 

Kawai T, Watanabe T, Yamada T, Morita T, Furukawa Y, Tamaki S, Kawasaki M, Kikuchi A, Seo M, Nakamura J, et al. Coronary vasomotion after treatment with drug-coated balloons or drug-eluting stents: a prospective, open-label, single-centre randomised trial. EuroIntervention: J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2022;18(2):e140–8.

Article  Google Scholar 

Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Leibundgut G, Weilenmann D, Wohrle J, Richter S, Schreiber M, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018;392(10150):849–56.

Article  CAS  PubMed  Google Scholar 

Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010;121(24):2672–80.

Article  PubMed  Google Scholar 

Her AY, Shin ES, Kim S, Kim B, Kim TH, Sohn CB, Choi BJ, Park Y, Cho JR, Jeong YH. Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease. Cardiovasc Diabetol. 2023;22(1):120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeger RV, Farah A, Ohlow MA, Mangner N, Mobius-Winkler S, Weilenmann D, Wohrle J, Stachel G, Markovic S, Leibundgut G, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet. 2020;396(10261):1504–10.

Article  CAS  PubMed  Google Scholar 

Merinopoulos I, Gunawardena T, Corballis N, Bhalraam U, Reinhold J, Wickramarachchi U, Maart C, Gilbert T, Richardson P, Sulfi S, et al. Assessment of Paclitaxel Drug-Coated Balloon only Angioplasty in STEMI. JACC Cardiovasc Interventions. 2023;16(7):771–9.

Article  Google Scholar 

Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, Vink MA. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute myocardial infarction: the REVELATION Randomized Trial. JACC Cardiovasc Interventions. 2019;12(17):1691–9.

Article  Google Scholar 

Rissanen TT, Uskela S, Eranen J, Mantyla P, Olli A, Romppanen H, Siljander A, Pietila M, Minkkinen MJ, Tervo J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. 2019;394(10194):230–9.

Article  PubMed  Google Scholar 

Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Drug-coated balloon for De Novo Coronary Artery Disease: JACC State-of-the-art review. J Am Coll Cardiol. 2020;75(9):1061–73.

Article  CAS  PubMed  Google Scholar 

Colombo A, Leone PP, Ploumen EH, von Birgelen C. Drug-coated balloons as a first choice for patients with de novo lesions: pros and cons. EuroIntervention: J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2024;20(2):e120–2.

Article  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.

Article  CAS  PubMed  Google Scholar 

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 2023, 148(9):e9-e119.

Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, et al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the global leaders trial. Eur Heart J. 2019;40(31):2595–604.

Article  CAS  PubMed  Google Scholar 

Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, Levenson B, Möbius-Winkler S, Bruch L, Fischer D, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiology: Official J German Cardiac Soc. 2013;102(11):785–97.

Article  CAS  Google Scholar 

Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interventions. 2020;13(12):1391–402.

Article  Google Scholar 

Zhu Z, Han H, Zhu J, Zhang J, Du R, Ni J, Ying C, An X, Zhang R. Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Biomed Mater Eng. 2015;26(1–2):79–88.

CAS  PubMed  PubMed Central  Google Scholar 

Zhu J, Liu L, Zhu Z, Yang Z, Hu J, Ding F, Zhou Y, Su X, Ge J, Liu X, et al. A randomized comparison of a novel iopromide-based paclitaxel-coated balloon shenqi versus SeQuent please for the treatment of in-stent restenosis. Coron Artery Dis. 2021;32(6):526–33.

Article  PubMed  Google Scholar 

Xu B, Zhang Q, Yang YJ, Qiao SB, Zhang RY, Zhang JS, Hu J, Qin XW, Hong T, Li JP, et al. Sirolimus-eluting cobalt-chromium stents: two-year clinical results from first-in-man study on the Firebird 2 stent. Chin Med J (Engl). 2008;121(6):492–7.

Article  CAS  PubMed  Google Scholar 

Han Y, Xu B, Jing Q, Lu S, Yang L, Xu K, Li Y, Li J, Guan C, Kirtane AJ, et al. A randomized comparison of novel biodegradable polymer- and durable polymer-coated cobalt-chromium sirolimus-eluting stents. JACC Cardiovasc Interventions. 2014;7(12):1352–60.

Article  Google Scholar 

Ge JB, Zhang F, Qian JY, Ge L, Liu XB, Zhou J. Six-month clinical outcomes of Firebird 2TM sirolimus-eluting stent implantation in real-world patients with coronary artery diseases. Chin Med J (Engl). 2011;124(6):831–5.

PubMed  Google Scholar 

Chang CC, Kogame N, Onuma Y, Byrne RA, Capodanno D, Windecker S, Morel MA, Cutlip DE, Krucoff MW, Stone GW, et al. Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. EuroIntervention: J EuroPCR Collab Working Group Interventional Cardiol Eur Soc Cardiol. 2020;15(13):1190–8.

Article  Google Scholar 

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39(3):213–60.

Article  PubMed  Google Scholar 

Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018;39(23):2192–207.

Article  PubMed  Google Scholar 

Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and interventions (SCAI). J Am Coll Cardiol. 2013;62(17):1563–70.

Article  PubMed  PubMed Central  Google Scholar 

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial I: fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–64.

Article  PubMed  Google Scholar 

Lansky AJ, Messé SR, Brickman AM, Dwyer M, van der Bart H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, et al. Proposed standardized neurological endpoints for Cardiovascular clinical trials: an Academic Research Consortium Initiative. Eur Heart J. 2018;39(19):1687–97.

Article  PubMed  Google Scholar 

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47.

Article  PubMed  Google